Cargando…
Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization
BACKGROUND: Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are associated with high mortality rates. The optimal treatment regimen for CRAB has not been defined. Cefiderocol has been recently introduced in the armamentarium against CRAB but there is concern about treatment-emergent r...
Autores principales: | Tiseo, Giusy, Giordano, Cesira, Leonildi, Alessandro, Riccardi, Niccolò, Galfo, Valentina, Limongi, Federica, Nicastro, Manuela, Barnini, Simona, Falcone, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265591/ https://www.ncbi.nlm.nih.gov/pubmed/37325251 http://dx.doi.org/10.1093/jacamr/dlad078 |
Ejemplares similares
-
Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae–Producing KPC-31, a D179Y Variant of KPC-3
por: Tiseo, Giusy, et al.
Publicado: (2021) -
Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review
por: Principe, Luigi, et al.
Publicado: (2022) -
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii
por: Moussa, Samir H., et al.
Publicado: (2023) -
Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections
por: Watkins, Richard R, et al.
Publicado: (2023) -
1254. In vitro activity of sulbactam-durlobactam against recent global clinical Acinetobacter baumannii-calcoaceticus complex isolates
por: McLeod, Sarah, et al.
Publicado: (2020)